Table of Contents Author Guidelines Submit a Manuscript
Advances in Virology
Volume 2016 (2016), Article ID 7971847, 10 pages
http://dx.doi.org/10.1155/2016/7971847
Research Article

Immunogenicity of RSV F DNA Vaccine in BALB/c Mice

1Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA
2Faculty of Engineering, Bioengineering Department, Celal Bayar University, Muradiye, Manisa, Turkey
3College of Medicine, University of South Alabama, Mobile, AL, USA
4Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA

Received 25 March 2016; Accepted 12 May 2016

Academic Editor: Itabajara da Silva Vaz Jr.

Copyright © 2016 Erdal Eroglu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Hacking and J. Hull, “Respiratory syncytial virus—viral biology and the host response,” Journal of Infection, vol. 45, no. 1, pp. 18–24, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. E. D. Clercq, “Chemotherapy of respiratory syncytial virus infections: the final breakthrough,” International Journal of Antimicrobial Agents, vol. 45, no. 3, pp. 234–237, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. G. F. Langley and L. J. Anderson, “Epidemiology and prevention of respiratory syncytial virus infections among infants and young children,” Pediatric Infectious Disease Journal, vol. 30, no. 6, pp. 510–517, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9859, pp. 2095–2128, 2012. View at Publisher · View at Google Scholar
  5. H. Nair, D. J. Nokes, B. D. Gessner et al., “Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis,” The Lancet, vol. 375, no. 9725, pp. 1545–1555, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Modjarrad, B. Giersing, D. C. Kaslow, P. G. Smith, and V. S. Moorthy, “WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015,” Vaccine, vol. 34, no. 2, pp. 190–197, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. M. S. A. Gilman, S. M. Moin, V. Mas et al., “Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the rsv fusion glycoprotein,” PLoS Pathogens, vol. 11, no. 7, Article ID e1005035, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. J. S. McLellan, M. Chen, M. G. Joyce et al., “Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus,” Science, vol. 342, no. 6158, pp. 592–598, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. K. A. Swanson, E. C. Settembre, C. A. Shaw et al., “Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 23, pp. 9619–9624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. Bueno, P. A. González, C. A. Riedel, L. J. Carreño, A. E. Vásquez, and A. M. Kalergis, “Local cytokine response upon respiratory syncytial virus infection,” Immunology Letters, vol. 136, no. 2, pp. 122–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. P. DeVincenzo, R. J. Whitley, R. L. Mackman et al., “Oral GS-5806 activity in a respiratory syncytial virus challenge study,” The New England Journal of Medicine, vol. 371, no. 8, pp. 711–722, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Murray, S. Saxena, and M. Sharland, “Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals,” Archives of Disease in Childhood, vol. 99, no. 5, pp. 469–473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. J. S. Lee, Y.-M. Kwon, H. S. Hwang et al., “Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus,” Vaccine, vol. 32, no. 44, pp. 5866–5874, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Liang, S. Surman, E. Amaro-Carambot et al., “Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate,” Journal of Virology, vol. 89, no. 18, pp. 9499–9510, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Mok, S. Lee, T. J. Utley et al., “Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats,” Journal of Virology, vol. 81, no. 24, pp. 13710–13722, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J.-F. Valarcher and G. Taylor, “Bovine respiratory syncytial virus infection,” Veterinary Research, vol. 38, no. 2, pp. 153–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. M. Langedijk, R. H. Meloen, G. Taylor, J. M. Furze, and J. T. Van Oirschot, “Antigenic structure of the central conserved region of protein G of bovine respiratory syncytial virus,” Journal of Virology, vol. 71, no. 5, pp. 4055–4061, 1997. View at Google Scholar · View at Scopus
  18. S. R. Singh, V. A. Dennis, C. L. Carter et al., “Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model,” Vaccine, vol. 25, no. 33, pp. 6211–6223, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Ternette, B. Tippler, K. Überla, and T. Grunwald, “Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus,” Vaccine, vol. 25, no. 41, pp. 7271–7279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. T. R. Johnson, R. A. Parker, J. E. Johnson, and B. S. Graham, “IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge,” Journal of Immunology, vol. 170, no. 4, pp. 2037–2045, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Huang, S. L. Cyr, D. S. Burt, and R. Anderson, “Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine,” Journal of Clinical Virology, vol. 44, no. 4, pp. 287–291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. L. Harcourt, L. J. Anderson, W. Sullender, and R. A. Tripp, “Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles,” Vaccine, vol. 22, no. 17-18, pp. 2248–2260, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. B. R. Murphy, A. V. Sotnikov, L. A. Lawrence, S. M. Banks, and G. A. Prince, “Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization,” Vaccine, vol. 8, no. 5, pp. 497–502, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Wu, V. A. Dennis, S. R. Pillai, and S. R. Singh, “RSV fusion (F) protein DNA vaccine provides partial protection against viral infection,” Virus Research, vol. 145, no. 1, pp. 39–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. L. Collins, Y. T. Huang, and G. W. Wertz, “Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 24, pp. 7683–7687, 1984. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Eroglu, P. M. Tiwari, A. B. Waffo et al., “A nonviral pHEMA+chitosan nanosphere-mediated high-efficiency gene delivery system,” International Journal of Nanomedicine, vol. 8, pp. 1403–1415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Mentel, U. Wegner, R. Bruns, and L. Gürtler, “Real-time PCR to improve the diagnosis of respiratory syncytial virus infection,” Journal of Medical Microbiology, vol. 52, no. 10, pp. 893–896, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Racine and G. M. Winslow, “IgM in microbial infections: taken for granted?” Immunology Letters, vol. 125, no. 2, pp. 79–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Ponnuraj, A. R. Hayward, A. Raj, H. Wilson, and E. A. Simones, “Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macac radiata) pre-immunized with a formaline-inactivated RSV vaccine,” Journal of General Virology, vol. 82, pp. 2663–2674, 2001. View at Publisher · View at Google Scholar
  30. W. V. Kalina, A. R. Woolums, R. D. Berghaus, and L. J. Gershwin, “Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle,” Vaccine, vol. 22, no. 11-12, pp. 1465–1474, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. E. Waris, C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson, “Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern,” Journal of Virology, vol. 70, no. 5, pp. 2852–2860, 1996. View at Google Scholar · View at Scopus
  32. P. A. Piedra, P. R. Wyde, W. L. Castleman et al., “Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon,” Vaccine, vol. 11, no. 14, pp. 1415–1423, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. G. J. Nabel, “Challenges and opportunities for development of an AIDS vaccine,” Nature, vol. 410, no. 6831, pp. 1002–1007, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Gurunathan, C.-Y. Wu, B. L. Freidag, and R. A. Seder, “DNA vaccines: a key for inducing long-term cellular immunity,” Current Opinion in Immunology, vol. 12, no. 4, pp. 442–447, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Hu, X. Huang, L. Tao, Y. Huang, B.-A. Cui, and H. Wang, “Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model,” Vaccine, vol. 27, no. 11, pp. 1758–1763, 2009. View at Publisher · View at Google Scholar · View at Scopus